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Abstract
Background: Dengue is the most common mosquito-borne viral disease in humans. However, the sensitivities of
warning signs (WSs) for identifying severe dengue in adults are low, and the utility of lactate levels for identifying
severe dengue in adults has not been verified. Therefore, we aimed to evaluate the diagnostic accuracy of using
peripheral venous lactate levels (PVL), as well as WSs established by the World Health Organization, for identifying
severe dengue.
Methods: We prospectively evaluated individuals hospitalized for dengue who were admitted to the Hospital for
Tropical Diseases in Thailand between May 2013 and January 2015. Blood samples to evaluate PVL levels were
collected at admission and every 24 h until the patient exhibited a body temperature of <37.8 °C for at least 24 h.
Data were recorded on a pre-defined case report form, including baseline characteristics, clinical parameters, and
laboratory findings.
Results: Among 125 patients with confirmed dengue, 105 (84.0 %) patients had non-severe dengue, and 20
(16.0 %) patients had severe dengue. The presence of clinical fluid accumulation as a WS provided high sensitivity
(75.0 %, 95 % confidence interval [CI]: 50.9–91.3 %) and specificity (90.5 %, 95 % CI: 83.2–95.3 %). The PVL level at
admission was used to evaluate its diagnostic value, and receiver operating characteristic curve analysis revealed an
area under the curve of 0.84 for identifying severe dengue. At the optimal cutoff value (PVL: 2.5 mmol/L), the
sensitivity and specificity were 65.0 % (95 % CI: 40.8–84.6 %) and 96.2 % (95 % CI: 90.5–99.0 %), respectively. A
combined biomarker comprising clinical fluid accumulation and/or PVL of ≥2.5 mmol/L provided the maximum
diagnostic accuracy for identifying severe dengue, with a sensitivity of 90.0 % (95 % CI: 68.3–98.8 %) and a
specificity of 87.6 % (95 % CI: 79.8–93.2 %).
Conclusions: Clinical fluid accumulation and/or PVL may be used as a diagnostic biomarker of severe dengue
among adults. This biomarker may facilitate early recognition and timely treatment of patients with severe dengue,
which may reduce dengue-related mortality and hospital burden.
Keywords: Severe dengue, Lactate, Warning signs, Diagnostic accuracy, Prospective study
* Correspondence: wattanathum_anan@hotmail.com
2Pulmonary and Critical Care Division, Department of Medicine,
Phramongkutklao Hospital, 315 Rajvithi Road, Ratchathewi District, Bangkok
10400, Thailand
Full list of author information is available at the end of the article
© 2016 Thanachartwet et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Thanachartwet et al. BMC Infectious Diseases  (2016) 16:46 
DOI 10.1186/s12879-016-1386-5
Background
Dengue is the most common global mosquito-borne
viral disease in humans [1]. Dengue is currently endemic
in more than 125 countries, and Central and South
America, South-East Asia, and the Western Pacific re-
gion are the most seriously affected [2, 3]. In their 2020
goals for dengue, the World Health Organization
(WHO) called for a 25 % reduction in morbidity and a
50 % reduction in mortality [1]. The key to reducing
mortality from severe dengue is early recognition and
timely treatment before the patient develops dengue
shock and organ dysfunction [3].
Previous reports have demonstrated that there has
been an epidemic shift from children to adults regarding
those who experience more severe dengue [2, 4, 5]. In
Thailand, a previous study reported that the number of
adults with dengue has increased dramatically during re-
cent decades [4]; more so, approximately 27.9 % of all
hospitalized adults with dengue develop severe dengue,
according to the 2009 WHO definitions [6]. A recent
systematic review regarding the application of the 2009
WHO warning signs (WSs) for identifying severe dengue
revealed a wide range of sensitivities (59–98 %) and
specificities (41–99 %) [7]. In adults with dengue, the
WSs have low sensitivities for identifying severe dengue,
as they were developed based on findings that were lim-
ited by retrospective designs and small sample sizes [8, 9].
Unfortunately, using WSs to identify severe dengue in-
creases the hospital burden and work load of healthcare
personnel as much as two fold. This is especially true for
resource-limited countries and areas with endemic den-
gue, particularly Thailand [10, 11].
Following dengue virus infection, the complications of
dengue may be caused by an immunologic mechanism
that results in increased capillary permeability, which
leads to altered microcirculatory blood flow and ultim-
ately to decreased tissue perfusion during the critical
phase of dengue [12]. Under anaerobic conditions or in
tissues with poor perfusion, lactate is formed by the re-
duction of pyruvate via the enzyme lactate dehydrogen-
ase in order to produce ATP for cellular energy. In this
context, serum lactate has been demonstrated to be a
prognostic marker in critically ill patients [13, 14]. Sev-
eral reports have also demonstrated that serum lactate
in critically ill patients was correlated with in-hospital
mortality and organ dysfunction [15–21]. In a previous
study, we showed that serum lactate is an independent
factor for identifying severe dengue in adults [22]. Thus,
we hypothesized that elevated lactate levels might serve
as a diagnostic biomarker for identifying tissue hypoper-
fusion among patients with dengue before clinical mani-
festations of severe dengue develop. To investigate this
hypothesis, we performed this prospective observational
study among patients with dengue who were admitted
to the Hospital for Tropical Diseases in Bangkok,
Thailand. Using data from these patients, we evaluated
the diagnostic accuracy of peripheral venous lactate
(PVL) and WSs for identifying severe dengue.
Methods
Ethical considerations
The study’s design was approved by the Ethics Committee
of the Faculty of Tropical Medicine, Mahidol University
(MUTM 2013-008-02) and the Ethics Committee of
Phramongkutklao Hospital, Bangkok, Thailand (IRBRTA
1571/2013). The Standards for Reporting of Diagnostic
Accuracy (STARD) were followed in this study [23]. Prior
to participating in the study, written informed consent
was obtained from all patients, (and/or the patient's
guardians if the patient was 15–18 years old).
Study design
This prospective observational study was performed
among patients who were admitted to the Hospital for
Tropical Diseases (Faculty of Tropical Medicine, Mahidol
University, Bangkok, Thailand) between May 2013 and
January 2015. Individuals ≥15 years old were eligible for
inclusion if they presented with clinical indicators of
dengue, which were defined as acute fever and ≥2 of the
following symptoms: 1) headache, 2) retro-orbital pain
or ocular pain, 3) myalgia, 4) arthralgia, 5) rash, 6) a
positive tourniquet test (≥20 petechiae per 1 square
inch), or 7) leukopenia (defined as a white blood cell
count <5.0 × 103 cells/μL). In addition, to be eligible for
inclusion, participants had to have the presence of den-
gue viral infection confirmed via reverse-transcriptase
polymerase chain reaction (RT-PCR) from an admission
serum sample or dengue-specific immunoglobulin M
(IgM) and immunoglobulin G (IgG) using enzyme-
linked immunosorbent assays (ELISA) of paired serum
samples (taken upon admission and 2 weeks after ad-
mission). Patients with a history of underlying medical
illness, mixed infection, or who were currently pregnant
were excluded from this study.
Laboratory tests at admission included a complete
blood count, blood chemistry analysis, and assessment
of PVL levels. Blood samples for PVL were subsequently
collected every 24 h until the patient exhibited a body
temperature of <37.8 °C for at least 24 h. To exclude the
presence of other infections, hospitalized patients pro-
vided two blood cultures for microbiology analysis and
underwent a urinalysis and chest radiography at admis-
sion. Other diagnostic tests for infectious diseases were
also performed when clinical findings were suspect. The
treating physicians were blinded to the results of the
PVL tests. All patients with dengue received standard
treatment according to the 2009 WHO guidelines for
dengue [24]. All patient data, including baseline
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characteristics, clinical parameters, and laboratory find-
ings, were recorded on a pre-defined case report form.
Case definitions for dengue
Using the 2009 WHO dengue case definitions [24], we
classified patients as having either non-severe or severe
dengue on the basis of their clinical and laboratory data.
Patients with non-severe dengue were sub-categorized ac-
cording to the presence or absence of WSs. Non-severe
dengue without WSs was defined as an acute fever with
≥2 of the following symptoms: 1) nausea, 2) vomiting, 3)
rash, 4) myalgia, 5) arthralgia, 6) a positive tourniquet test,
or 7) leukopenia. The WSs included 1) abdominal pain; 2)
persistent vomiting (defined as vomiting with signs of de-
hydration during physical examination); 3) clinical fluid
accumulation that manifested as pleural effusion, ascites,
or a serum albumin level <3.5 g/dL; 4) lethargy; 5) a liver
span of >15 cm; 6) bleeding from a mucosal area, includ-
ing the nose, gums, gastrointestinal tract, or vagina; 7) an
increase in hematocrit of 2 % above the sex-specific refer-
ence range for a healthy Thai adult; and 8) a platelet count
of ≤100 × 103/μL. Patients were diagnosed with severe
dengue if they met all of the criteria for non-severe den-
gue, as well as at least one of the following: 1) severe
plasma leakage that caused shock or respiratory distress,
2) severe clinical bleeding (i.e., bleeding in the vital organs
or spontaneous bleeding from a mucosal area that re-
quired a blood transfusion), or 3) severe organ involve-
ment (evidenced by an aspartate aminotransferase [AST]
level >1,000 U/L, an alanine aminotransferase [ALT] level
>1,000 U/L, a serum creatinine level ≥3 times above base-
line, myocarditis, and/or encephalitis). Plasma leakage was
defined as a ≥20 % increase in hematocrit (above the refer-
ence range) or clinical evidence of fluid accumulation.
Shock was defined as a systolic blood pressure of
<90 mmHg with a <0.5 mL/kg/h decrease in urine output,
impaired consciousness, AST level >1,000 IU/L, or ALT
level >1,000 IU/L. Respiratory distress was defined as a re-
spiratory rate of ≥24 breaths/min with <95 % oxygen sat-
uration on room air and/or the need for oxygen therapy.
RT-PCR
Dengue viral RNA was extracted from each patient’s
serum using a 2-step PCR method, as described by
Lanciotti et al. [25] and modified using the methods
outlined by Reynes et al. [26]. The RNA was extracted
from the acute serum samples using the PureLink®
Viral RNA/DNA Mini Kit (Invitrogen™, USA), according
to the manufacturer’s instructions.
Serology for dengue viral infection
All sera were tested using 4 separate captures in ELISA
assays for IgM and IgG against the dengue virus and the
Japanese encephalitis virus, as described by Innis et al.
[27]. To differentiate between dengue and other flavivi-
rus infections, we determined the ratio of dengue IgM to
Japanese encephalitis virus IgM, with a ratio of ≥1.0 indi-
cating dengue virus infection and a ratio of <1.0 indicating
other flavivirus infection. The ratio of dengue IgM to den-
gue IgG was also calculated, with a ratio of ≥1.8 indicating
a primary dengue infection and a ratio of <1.8 indicating a
secondary dengue infection.
Measurement of peripheral venous lactate
Blood samples were collected from a vein in an upper
extremity without the use of a tourniquet. The 2 mL
blood sample was placed in a vacutainer that contained
sodium fluoride, and the sample was immediately placed
on ice, sent to the laboratory center, and analyzed for
lactate within 10 min of being drawn. A colorimetric
assay with an enzymatic reaction that converted lactate
to pyruvate was performed using an auto-analyzer
(Roche/Hitachi Cobas C Systems, USA), according to
the manufacturers' protocols. In this assay, L-lactate is
oxidized to pyruvate and hydrogen peroxide by lactate
oxidase, and the hydrogen peroxide reacts with peroxid-
ase to generate a colored dye. The intensity of the color
is directly proportional to the L-lactate concentration, as
measured by the increase in absorbance. Lactate levels
are expressed as mmol/L. The laboratory personnel were
blinded to the sample sources, and the coefficient of
variation for this assay in our laboratory was 1.1 %.
Sample size calculation
A previous retrospective study at the Hospital for Trop-
ical Diseases indicated that the incidence of severe den-
gue was 27.9 % among adults who were hospitalized
with dengue according to the 2009 WHO definitions [6].
However, it has also been estimated that the incidence
of severe dengue would be approximately 20 % among
dengue patients if they received close observation through-
out treatment and care during their hospitalization [22].
Based on this information, we calculated that a sample
size of 120 patients was needed for this study, using a spe-
cificity of 90 % with a confidence interval of ±6 %.
Statistical analysis
All data were analyzed using SPSS software (version
18.0; SPSS Inc., Chicago, IL). Numerical variables were
tested for normality using the Kolmogorov-Smirnov test.
Variables with non-normal distribution were summa-
rized as a median and inter-quartile range (IQR) and
were compared using the Mann–Whitney U test for 2-
group comparison. Categorical variables are expressed as
frequencies and percentages, and were analyzed using
the Chi-square test or Fisher’s exact test, as appropriate.
The optimal lactate cutoff value for identifying se-
vere dengue was determined using receiver operating
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characteristic (ROC) curves. Diagnostic parameters
were evaluated using 2 × 2 tables and 95 % confidence in-
tervals (CI) to determine their sensitivity, specificity, nega-
tive predictive value (NPV), positive predictive value
(PPV), positive likelihood ratio (LR+), and negative likeli-
hood ratio (LR–). All tests of significance were 2-sided,
with a p-value <0.05 indicating statistical significance.
Results
Patient characteristics
Among the 171 individuals with suspected dengue
who were admitted to the Hospital for Tropical Dis-
eases between May 2013 and January 2015, 46 patients
were excluded for various causes, including a history
of underlying illness (22 patients, 47.8 %), the pres-
ence of mixed infection (18 patients, 39.1 %), or nega-
tive RT-PCR/ELISA results for dengue (6 patients,
13.1 %). Thus, 125 hospitalized patients with con-
firmed dengue viral infection were included in this
study. Among these 125 patients, 105 (84.0 %) patients
had non-severe dengue, including 5 (4.8 %) patients
without WSs and 100 (95.2 %) patients with WSs.
Twenty (16.0 %) patients had severe dengue according
to the 2009 WHO definitions, including 15 (75.0 %)
patients with severe plasma leakage, 12 (80.0 %) pa-
tients with plasma leakage and shock, and 8 (53.3 %)
patients with plasma leakage and respiratory distress.
Among the 20 patients with severe dengue, 11
(55.0 %) patients had severe clinical bleeding. Eight
(40.0 %) patients had severe organ involvement, including
5 (62.5 %) patients with an AST level >1,000 U/L and/or
an ALT level >1,000 U/L, 4 (50.0 %) patients with a serum
creatinine level ≥3 times above the baseline, 2 (25.0 %) pa-
tients with myocarditis, and 1 (12.5 %) patient with en-
cephalitis (Fig. 1).
Comparison of clinical and laboratory characteristics of
patients with severe and non-severe dengue
At admission, patients with severe and non-severe den-
gue had similar clinical and laboratory characteristics.
However, patients with severe dengue were significantly
more likely to be older (median [IQR]: 36.5 [20.2–50.5]
years vs. 23.0 [19.0–33.5] years, p = 0.010). In addition,
patients diagnosed with severe dengue were more likely
to present with a longer duration of fever (median [IQR]:
5.0 [4.0–6.0] days vs. 4.0 [3.0–5.0] days, p = 0.003), have
persistent vomiting (8/20 [40.0 %] patients vs. 12/105
[11.4 %] patients, p = 0.004), and have an increased re-
spiratory rate (median [IQR]: 22 [20–24] breaths/min vs.
20 [18–22] breaths/min, p = 0.019). These patients were
also more likely to have mucosal bleeding (14/20 [70.0 %]
patients vs. 39/105 [37.1 %] patients, p = 0.013), skin
bleeding (13/20 [65.0 %] patients vs. 22/105 [21.0 %],
p < 0.001), a liver span of >15 cm (12/20 [60.0 %] patients
vs. 17/105 [16.2 %] patients, p < 0.001], and clinical fluid
accumulation (15/20 [75.0 %] patients vs. 10/105 [9.5 %]
patients, p < 0.001). In addition, patients with severe den-
gue had significantly higher levels of AST (median [IQR]:
228 [162–760] IU/L vs. 71 [36–156] IU/L, p < 0.001), ALT
(median [IQR]: 172 [114–415] IU/L vs. 46 [18–102] IU/L,
p < 0.001), and lactate (median [IQR]: 2.7 [1.8–3.1] mmol/
L vs. 1.4 [1.2–1.8] mmol/L, p < 0.001). Furthermore,
patients with severe dengue had significantly lower
platelet counts (median [IQR]: 41.5 [11.2–63.5] × 103/
μL vs. 90.0 [56.0–145.5] × 103/μL, p < 0.001] and albu-
min levels (median [IQR]: 3.6 [3.1–4.2] g/dL vs. 4.3
[4.0–4.5] g/dL, p < 0.001). Moreover, patients with se-
vere dengue had a significantly longer hospitalization
duration compared to patients with non-severe dengue
(median [IQR]: 4.8 [2.9–9.8] days vs. 3.7 [2.7–4.9] days,
p = 0.012) (Table 1).
Fig. 1 Study flow chart. WHO World Health Organization
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Table 1 Baseline clinical and laboratory characteristics of 125 patients hospitalized with dengue
Characteristics All dengue cases The 2009 WHO dengue case definitions p-value
Severe dengue Non-severe dengue
n No. (%) n No. (%) n No. (%)
Baseline characteristics
Age (years), median (IQR) 125 24.0 (19.0–36.0) 20 36.5 (20.2–50.5) 105 23.0 (19.0–33.5) 0.010c
Sex, female 125 57 (45.6) 20 11 (55.0) 105 46 (43.8) 0.499a
Residential area, Bangkok 125 104 (83.2) 20 18 (90.0) 105 86 (81.9) 0.523b
Clinical symptoms
Fever (days), median (IQR) 125 4.0 (3.0–5.0) 20 5.0 (4.0–6.0) 105 4.0 (3.0–5.0) 0.003c
Myalgia 125 114 (91.2) 20 19 (95.0) 105 95 (90.5) 1.000b
Headache 125 109 (87.2) 20 17 (85.0) 105 92 (87.6) 0.720b
Lethargy 125 94 (75.2) 20 18 (90.0) 105 76 (72.4) 0.155b
Nausea 125 88 (70.4) 20 14 (70.0) 105 74 (70.5) 1.000a
Retro-orbital pain 125 80 (64.0) 20 11 (55.0) 105 69 (65.7) 0.509a
Abdominal pain 125 53 (42.4) 20 9 (45.0) 105 44 (41.9) 0.992a
Arthralgia 125 41 (32.8) 20 9 (45.0) 105 32 (30.5) 0.313a
Persistent vomiting 125 20 (16.0) 20 8 (40.0) 105 12 (11.4) 0.004b
Physical examinations
Temperature (°C), median (IQR) 125 38.5 (37.8–39.2) 20 38.5 (37.7–39.0) 105 38.5 (37.8–39.2) 0.580c
Mean arterial pressure (mmHg), median (IQR) 125 86 (78–92) 20 84 (70–93) 105 86 (78–92) 0.522c
Heart rate (beats/min), median (IQR) 125 80 (66–90) 20 83 (70–91) 105 79 (66–90) 0.457c
Respiratory rate (breaths/min), median (IQR) 125 22 (20–22) 20 22 (20–24) 105 20 (18–22) 0.019c
Tourniquet test, positive 125 106 (84.8) 20 15 (75.0) 105 91 (86.7) 0.187b
Rash 125 55 (44.0) 20 9 (45.0) 105 46 (43.8) 1.000a
Mucosal bleeding 125 53 (42.4) 20 14 (70.0) 105 39 (37.1) 0.013a
Skin bleeding 125 35 (28.0) 20 13 (65.0) 105 22 (21.0) <0.001a
Liver span of >15 cm 125 29 (23.2) 20 12 (60.0) 105 17 (16.2) <0.001b
Clinical fluid accumulation 125 25 (20.0) 20 15 (75.0) 105 10 (9.5) <0.001b
Confirmation tests for dengue
Dengue RT-PCR, positive 125 79 (63.2) 20 15 (75.0) 105 64 (61.0) 1.000b
Serotypes 1 or 4 79 22 (27.8) 15 4 (26.7) 64 18 (28.1)
Serotypes 2 or 3 79 57 (72.2) 15 11 (73.3) 64 46 (71.9)
Dengue ELISA, positive 125 119 (95.2) 20 20 (100) 105 99 (94.3) 0.526b
Primary dengue infection 119 4 (3.4) 20 1 (5.0) 99 3 (3.0)
Secondary dengue infection 119 115 (96.6) 20 19 (95.0) 99 96 (97.0)
Complete blood counts
Hemoglobin, median (IQR), g/dL 125 13.8 (12.8–14.9) 20 13.9 (12.7–16.7) 105 13.8 (12.8–14.9) 0.540c
Hematocrit, median (IQR), % 125 41.6 (38.1–44.4) 20 40.7 (37.1–48.9) 105 41.6 (38.4–44.4) 0.882c
WBC, median (IQR), ×103/μL 125 3.0 (2.2–4.8) 20 3.6 (2.1–6.8) 105 3.0 (2.2–4.6) 0.324c
Platelet counts, median (IQR), ×103/μL 125 78.0 (48.0–127.0) 20 41.5 (11.2–63.5) 105 90.0 (56.0–145.5) <0.001c
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Diagnostic value of the 2009 WHO warning signs for
identifying severe dengue
The diagnostic values of the 2009 WHO WSs for identi-
fying severe dengue at admission are shown in Table 2.
The sensitivities for all WSs were low, except for leth-
argy (90.0 %, 95 % CI: 68.3–98.8 %), clinical fluid accu-
mulation (75.0 %, 95 % CI: 50.9–91.3 %), and mucosal
bleeding (70.0 %, 95 % CI: 45.7–88.1 %). Similarly, the
specificities for all WSs were low, except for persistent
vomiting (88.6 %, 95 % CI: 80.9–94.0 %), clinical fluid
accumulation (90.5 %, 95 % CI: 83.2–95.3 %), and liver
span of >15 cm (83.8 %, 95 % CI: 75.4–90.3 %). The
PPVs and LR+ values for the WSs were low, although
the NPVs for the WSs were high. The LR– values for
the WSs ranged from 0.3 to 0.9, which indicated a min-
imal to slightly decreased chance of developing severe
dengue. However, the area under the ROC (AUROC) for
the number of WSs in identifying severe dengue was
0.82 (95 % CI: 0.72–0.93) (Fig. 2a). The optimal sensitiv-
ity (70.0 %, 95 % CI: 45.7–88.1 %) and specificity
(80.0 %, 95 % CI: 71.1–87.2 %) were obtained using ≥4
WSs, which provided a low PPV (40.0 %, 95 % CI: 23.9–
57.9 %) and a high NPV (93.3 %, 95 % CI: 86.0–97.5 %),
as well as a LR+ of 3.5 (95 % CI: 2.2–5.6) and a LR– of
0.4 (95 % CI: 0.2–0.7). Therefore, clinical fluid accumu-
lation as a WS demonstrated good diagnostic value for
identifying severe dengue among patients hospitalized
with dengue.
Diagnostic value of PVL for identifying severe dengue
We initially evaluated the diagnostic value of PVL for
identifying severe dengue at admission. The AUROC for
Table 1 Baseline clinical and laboratory characteristics of 125 patients hospitalized with dengue (Continued)
Blood biochemistry
Creatinine, median (IQR), mg/dL 125 0.8 (0.6–1.0) 20 0.8 (0.6–1.1) 105 0.9 (0.7–1.0) 0.859c
Albumin, median (IQR), g/dL 125 4.2 (3.9–4.5) 20 3.6 (3.1–4.2) 105 4.3 (4.0–4.5) <0.001c
AST, median (IQR), IU/L 125 94 (38–202) 20 228 (162–760) 105 71 (36–156) <0.001c
ALT, median (IQR), IU/L 125 65 (22–148) 20 172 (114–415) 105 46 (18–102) <0.001c
Lactate level, median (IQR), mmol/L 125 1.5 (1.2–1.9) 20 2.7 (1.8–3.1) 105 1.4 (1.2–1.8) <0.001c
Duration of hospitalization (days), median (IQR) 125 3.9 (2.8–5.0) 20 4.8 (2.9–9.8) 105 3.7 (2.7–4.9) 0.012c
aChi-square test; bFisher’s exact test; cMann-Whitney U test; WHO World Health Organization; IQR interquartile range; RT-PCR reverse-transcriptase polymerase chain
reaction; ELISA enzyme-linked immunosorbent assay; WBC white blood cell count; AST aspartate aminotransferase; ALT alanine aminotransferase




















Abdominal pain 9 44 45.0(23.1–68.5) 58.1(48.1–67.7) 17.0(8.1–29.8) 84.7(74.3–92.1) 1.1(0.6–1.8) 0.9(0.6–1.4)
Persistent vomiting 8 12 40.0(19.1–64.0) 88.6(80.9–94.0) 40.0(19.1–64.0) 88.6(80.9–94.0) 3.5(1.6–7.4) 0.7(0.5–1.0)
Clinical fluid accumulation 15 10 75.0(50.9–91.3) 90.5(83.2–95.3) 60.0(38.7–78.9) 95.0(88.7–98.4) 7.9(4.2–15.0) 0.3(0.1–0.6)
Lethargy 18 76 90.0(68.3–98.8) 27.6(19.3–37.2) 19.2(11.8–28.6) 93.6(78.6–99.2) 1.2(1.0–1.5) 0.4(0.1–1.4)
Liver span of >15 cm 12 17 60.0(36.0–80.9) 83.8(75.4–90.3) 41.4(23.5–61.1) 91.7(84.2–96.3) 3.7(2.1–6.5) 0.5(0.3–0.8)
Mucosal bleeding 14 39 70.0(45.7–88.1) 62.9(52.9–72.1) 26.4(15.3–40.3) 91.7(82.7–96.9) 1.9(1.3–2.8) 0.5(0.2–1.0)
Hematocrit >2 % and
platelets ≤100 × 103/μL
12 42 60.0(36.0–80.9) 60.0(50.0–69.4) 22.2(12.0–35.6) 88.7(79.0–95.0) 1.5(1.0–2.3) 0.7(0.4–1.2)
Number of warning signs
≥ 1 20 95 100.0(83.2–100.0) 9.5(4.7–16.8) 17.4(11.0–25.6) 100.0(69.2–100.0) 1.1(1.0–1.2) 0
≥ 2 19 71 95.0(75.1–99.9) 32.4(23.6–42.1) 21.1(13.2–31.0) 97.1(85.1–99.9) 1.4(1.2–1.7) 0.2(0–1.1)
≥ 3 17 43 85.0(62.1–96.8) 59.0(49.0–68.6) 28.3(17.4–41.4) 95.4(87.1–99.0) 2.1(1.6–2.8) 0.2(0.1–0.7)
≥ 4 14 21 70.0(45.7–88.1) 80.0(71.1–87.2) 40.0(23.9–57.9) 93.3(86.0–97.5) 3.5(2.2–5.6) 0.4(0.2–0.7)
≥ 5 11 8 55.0(31.5–76.9) 92.4(85.5–96.6) 57.9(33.5–79.8) 91.5(84.5–96.0) 7.2(3.3–15.7) 0.5(0.3–0.8)
≥ 6 5 2 25.0(8.7–49.1) 98.1(93.3–99.8) 71.4(29.0–96.3) 87.3(79.9–92.7) 13.1(2.7–63.0) 0.8(0.6–1.0)
WHO World Health Organization; CI confidence interval; PPV positive predictive value; NPV negative predictive value; LR+ positive likelihood ratio; LR– negative
likelihood ratio
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PVL in identifying severe dengue was 0.84 (95 % CI:
0.72–0.97) (Fig. 2b). At the optimal PVL cutoff value of
2.5 mmol/L, the sensitivity was 65.0 % (95 % CI: 40.8–
84.6 %), the specificity was 96.2 % (95 % CI: 90.5–
99.0 %), the PPV was 76.5 % (95 % CI: 50.1–93.2 %), the
NPV was 93.5 % (95 % CI: 87.1–97.4 %), the LR+ was
17.1 (95 % CI: 6.2–47.0), and the LR– was 0.4 (95 % CI:
0.2–0.7) (Table 3). To improve the diagnostic accuracy
for identifying severe dengue, we developed a combined
biomarker consisting of clinical fluid accumulation and/
or PVL ≥2.5 mmol/L, which revealed improvements in
sensitivity (90.0 %, 95 % CI: 68.3–98.8 %), specificity
(87.6 %, 95 % CI: 79.8–93.2 %), PPV (58.1 %, 95 % CI:
39.1–75.4 %), NPV (97.9 %, 95 % CI: 92.5–99.7 %), LR+
(7.3, 95 % CI: 4.3–12.3), and LR– (0.1, 95 % CI: 0–0.4)
(Table 3).
Daily changes in PVL and daily fluid intake in patients
with severe and non-severe dengue
We analyzed the daily changes in PVL levels during
hospitalization among patients with severe and non-
severe dengue. Patients with severe dengue had signifi-
cantly higher PVL levels (compared to patients with
non-severe dengue) at admission through day 3 of
hospitalization. However, they exhibited a decrease in
median PVL levels to <2.0 mmol/L on days 3 and
thereafter (Fig. 3a). To determine the amount of fluid
intake during hospitalization, we evaluated daily oral
and intravenous fluid intake to determine the total
fluid received among patients with severe and non-
severe dengue. The amount of fluid intake was signifi-
cantly lower among patients with severe dengue than
those with non-severe dengue during day 1 through
day 6 of hospitalization. In addition, the amount of
intravenous fluid administered was significantly higher
among patients with severe dengue than among those
with non-severe dengue during day 1 and day 2 of
hospitalization. However, the total fluid received was
similar in both groups (Fig. 3b). Regarding the type of
intravenous fluid, all patients with non-severe dengue
received 0.9 % sodium chloride with or without dex-
trose as fluid therapy. Of 20 patients with severe den-
gue, 17 (85.0 %) patients received 0.9 % sodium
chloride with or without dextrose and 3 (15.0 %) pa-
tients received Ringer’s acetate with or without dex-
trose as initial fluid resuscitation. However, 5 (25.0 %)
patients received dextran and 4 (20.0 %) patients re-
ceived 5 % albumin for additional fluid resuscitation.
Discussion
A patient’s lactate level is a biomarker for the severity of
systemic hypoperfusion independent of organ failure and
shock [20]. In addition, elevated arterial or central ven-
ous lactate can predict in-hospital mortality in many
conditions and diseases, including infection, sepsis, liver
disease, trauma, and cardiac arrest [14]. Moreover, our
previous studies revealed that hospitalized adults with
dengue who had PVL levels ≥2.0 mmol/L at admission
were at risk for the development of severe dengue (odd
ratio, 7.340) [22]. Nevertheless, the utility of lactate
levels for identifying severe dengue in adults has not
been verified thus far, and we hypothesized that elevated
lactate levels might be a diagnostic biomarker for pa-
tients with dengue and tissue hypoperfusion before they
develop clinical symptoms of severe dengue.
Fig. 2 ROC curves for 2009 WHO warning signs and peripheral venous
lactate in identifying severe dengue. a The AUROC for the number of
2009 WHO warning signs at admission was 0.82 (95 % confidence
interval [95 % CI]: 0.72–0.93). b The AUROC for peripheral venous
lactate at admission was 0.84 (95 % CI: 0.72–0.97). AUROC area
under the receiver operating characteristics; ROC receiver operating
characteristics; WHO World Health Organization
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Among the 125 hospitalized individuals with con-
firmed dengue viral infection, 105 (84.0 %) patients had
non-severe dengue and 20 (16.0 %) patients had severe
dengue. Interestingly, this incidence of severe dengue
was lower than the incidence found in our previous
retrospective study (27.9 %) [6]. This discrepancy may
be due to the close observation and management of pa-
tients who participated in this prospective study. Our re-
sults also revealed that severe plasma leakage (75.0 %)
was the most common complication among patients
with severe dengue, which validates findings from a pre-
vious study [28]. Our analyses also revealed that most
WSs (and the number of WSs) provided low specificities
and sensitivities for identifying severe dengue. The one
exception was the presence of clinical fluid accumulation
(sensitivity: 75.0 %, specificity: 90.5 %, PPV: 60.0 %, NPV:
95.0 %, LR+: 7.9, and LR–: 0.3); previous studies have re-
ported similar findings [8, 9].
When we evaluated the diagnostic value of PVL levels
at admission, we found that the optimal PVL cutoff
value of 2.5 mmol/L yielded a sensitivity of 65.0 %, spe-
cificity of 96.2 %, PPV of 76.5 %, NPV of 93.5 %, LR+ of
17.1, and LR– of 0.4. Similarly, a previous systematic
review of lactate levels among patients with suspected
infection revealed that patients with lactate levels of
2.0–3.9 mmol/L had an increased risk of progressive
organ dysfunction and in-hospital mortality, including
patients without hypotension [29, 30]. The combined
biomarker of clinical fluid accumulation and/or PVL
level of ≥2.5 mmol/L provided the maximum diagnostic
accuracy (sensitivity: 90.0 %, specificity: 87.6 %, PPV:
58.1 %, NPV: 97.9 %, LR+: 7.3, and LR–: 0.1) for identi-
fying severe dengue. These findings might be due to
plasma leakage resulting from increased microvascular
permeability that then leads to elevated hematocrit
levels and/or clinical fluid accumulation; this may
subsequently cause impaired microvascular perfusion,
resulting in elevated lactate levels and eventually shock
with organ dysfunction [31, 32]. Therefore, the com-
bined biomarker of clinical fluid accumulation and/or
PVL levels ≥2.5 mmol/L could provide the maximum
diagnostic accuracy for identifying severe dengue.
Regarding fluid therapy for patients with dengue in-
cluded in this study, the type and amount of fluid ther-
apy were adjusted on the basis of the WHO South East
Asia Regional Organization (SEARO) guidelines [2]. The
majority of patients received 0.9 % sodium chloride with
or without dextrose as initial fluid therapy. In patients
with severe dengue, colloids including dextran and 5 %
albumin were used as additional fluid resuscitation. Pa-
tients with severe dengue received a significantly lower
amount of oral fluid intake per day during day 1 and day
6 of hospitalization, but the amount of intravenous fluid
administered per day was significantly higher during day
1 and day 2 of hospitalization. However, the total fluid
intake per day was similar in both groups. After fluid
therapy, the PVL levels decreased, but the PVL levels
were significantly higher among patients with severe
dengue than among those with non-severe dengue dur-
ing day 1 and day 3 of hospitalization.
Our study was designed as a prospective observational
study, which could minimize the risk of missing data
and reduce bias. Blood samples were regularly collected
under blinded conditions for treating physicians and in-
vestigators in order to demonstrate, without bias, the dy-
namic changes of PVL throughout the febrile phase as
well as the critical and recovery periods. However, this
study had some limitations. First, we recruited only pa-
tients with dengue at a single center for tropical diseases
in Thailand, which is likely not representative of the glo-
bal population of patients with dengue. Second, we en-
rolled only patients who were hospitalized with dengue.
Table 3 Diagnostic value of lactate at admission and a combination of clinical fluid accumulation with lactate at admission















Lactate at admission (mmol/L)
≥ 1.0 mmol/L 19 96 95.0(75.1–99.9) 8.6(4.0–15.6) 16.5(10.2–24.6) 90.0(55.5–99.8) 1.0(0.9–1.2) 0.6(0.1–4.4)
≥ 1.5 mmol/L 18 51 90.0(68.3–98.8) 51.4(41.5–61.3) 26.1(16.2–38.1) 96.4(87.7–99.6) 1.8(1.4–2.4) 0.2(0.1–0.7)
≥ 2.0 mmol/L 14 15 70.0(45.7–88.1) 85.7(77.5– 91.8) 48.3(29.4–67.47) 93.8(86.9–97.7) 4.9(2.8–8.5) 0.4(0.2–0.7)
≥ 2.5 mmol/L 13 4 65.0(40.8–84.6) 96.2(90.5–99.0) 76.5(50.1–93.2) 93.5(87.1–97.4) 17.1(6.2–47.0) 0.4(0.2–0.7)
Clinical fluid accumulation and/or lactate at admission (mmol/L)
≥ 1.0 mmol/L 20 96 100.0(83.2–100.0) 8.6(4.0-15.6) 17.2(10.9–25.4) 100.0(66.4–100.0) 1.1(1.0–1.2) 0
≥ 1.5 mmol/L 20 55 100.0(83.2–100.0) 47.6(37.8–57.6) 26.7(17.1–38.1) 100.0(92.9–100.0) 1.9(1.6–2.3) 0
≥ 2.0 mmol/L 18 22 90.0(68.3–98.8) 79.1(70.0–86.4) 45.0(29.3–61.5) 97.6(91.8–99.7) 4.3(2.9–6.4) 0.1(0–0.5)
≥ 2.5 mmol/L 18 13 90.0(68.3–98.8) 87.6(79.8–93.2) 58.1(39.1–75.4) 97.9(92.5–99.7) 7.3(4.3–12.3) 0.1(0–0.4)
WHO World Health Organization; CI confidence interval; PPV positive predictive value; NPV negative predictive value; LR+ positive likelihood ratio; LR– negative
likelihood ratio
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Third, patients were admitted to the hospital at different
times after fever onset, but all patients with dengue were
admitted during the febrile phase.
Conclusions
The presence of clinical fluid accumulation and/or PVL
of ≥2.5 mmol/L could be used as a diagnostic biomarker
for severe dengue among patients hospitalized with
dengue. This biomarker might facilitate early recognition
and timely treatment of patients with severe dengue,
which can reduce dengue-related mortality, hospital
burden, and unnecessary hospitalizations.
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